Stay Updated with the Latest Calliditas Therapeutics AB (publ) CALT News in Real Time
Find CALT news now at Meyka AI. Stay informed with the latest Calliditas Therapeutics AB (publ) stocks updates, including price news, market analysis, and expert insights.
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal, Offering Nearly 50% Premium
AbbVie made a major move in the biotech sector on June 22, 2026, announcing a $10.9 billion deal to acquire Apogee Therapeutics. The transaction offers Apogee shareholders nearly a 50% premium and gives AbbVie access to a promising pipeline of immunology treatments. As competition grows in the market for inflammatory disease therapies, this acquisition could…
Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns
French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead…
IMMX Maintained at Buy by H.C. Wainwright, May 2026
H.C. Wainwright maintains Buy rating on IMMX, raises price target to $20 from $15 on May 22, 2026.
XOMA Downgraded to Hold from Buy at Benchmark May 22
Benchmark downgraded XOMA to Hold from Buy on May 22, 2026. Stock trades at $41.65 with mixed analyst sentiment.
LBGUF Earnings Beat: L E Lundbergföretagen Q2 2026 Results
LBGUF reported Q2 2026 earnings on May 21, 2026 with $2.02 EPS and $868.45M revenue. Meyka AI rates the stock B+.
Xvivo Perfusion AB (XVIPY) Holds $6.54 as Organ Transplant Tech Faces Valuation Pressure
XVIPY stock trades flat at $6.54 USD on PNK. Medical device company faces high valuation multiples despite strong 6-month gains of 40%.
ROIV Maintained at Overweight by Piper Sandler, May 2026
Piper Sandler maintains Roivant Sciences (ROIV) at Overweight rating, citing mosliciguat Phase 2 catalysts and 2026 pipeline strength.
UTHR Maintained at Buy by Cowen & Co., May 2026
Cowen & Co. maintains Buy rating on United Therapeutics (UTHR) as a top biotech idea with strong fundamentals.
UTHR Stock: Officer Paul Mahon Sells 8,300 Shares May 22, 2026
United Therapeutics EVP Paul Mahon sold 8,300 stock options for $1.21M on May 21, 2026. Latest insider trading activity.